Paracetamol disposition and metabolite kinetics in patients with chronic renal failure
- PMID: 2744070
- DOI: 10.1007/BF00558162
Paracetamol disposition and metabolite kinetics in patients with chronic renal failure
Abstract
The disposition of paracetamol following an oral dose of 1.0 g was compared in 10 healthy volunteers, 7 patients with moderate chronic renal failure and 6 patients with end stage renal failure on maintenance haemodialysis. Paracetamol absorption was normal in the patients with renal failure. The mean plasma half-life of paracetamol from 2 to 8 h was similar in the 3 groups (2.1 to 2.3 h) but from 8 to 24 h it disappeared much more slowly in the renal failure patients (half-life 11.7 compared with 4.9 h in the healthy volunteers). Plasma concentrations of paracetamol glucuronide and sulphate conjugates were greatly increased in the patients with moderate renal failure and the mean plasma half-lives were 30.5 and 21.8 h respectively compared with about 3 h in the healthy volunteers. Plasma concentrations of these metabolites were even higher in the dialysis patients and there was no significant fall over 24 h. The cysteine and mercapturic acid conjugates of paracetamol could only be measured in plasma in the patients with renal failure and concentrations were very low. The fractional urinary recovery of paracetamol and its glucuronide, sulphate, cysteine and mercapturic acid conjugates was similar in healthy volunteers and patients with moderate renal failure.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
The disposition of paracetamol and its conjugates during multiple dosing in patients with end-stage renal failure maintained on haemodialysis.Eur J Clin Pharmacol. 1993;45(2):141-5. doi: 10.1007/BF00315495. Eur J Clin Pharmacol. 1993. PMID: 8223835
-
The disposition of paracetamol and the accumulation of its glucuronide and sulphate conjugates during multiple dosing in patients with chronic renal failure.Eur J Clin Pharmacol. 1991;41(1):43-6. doi: 10.1007/BF00280104. Eur J Clin Pharmacol. 1991. PMID: 1782975
-
Paracetamol and its metabolites in saliva and plasma in chronic dialysis patients.Br J Clin Pharmacol. 1996 Jan;41(1):41-7. doi: 10.1111/j.1365-2125.1996.tb00157.x. Br J Clin Pharmacol. 1996. PMID: 8824692
-
Kinetics and metabolism of paracetamol and phenacetin.Br J Clin Pharmacol. 1980 Oct;10 Suppl 2(Suppl 2):291S-298S. doi: 10.1111/j.1365-2125.1980.tb01812.x. Br J Clin Pharmacol. 1980. PMID: 7002186 Free PMC article. Review.
-
Clinical pharmacokinetics of paracetamol.Clin Pharmacokinet. 1982 Mar-Apr;7(2):93-107. doi: 10.2165/00003088-198207020-00001. Clin Pharmacokinet. 1982. PMID: 7039926 Review.
Cited by
-
Population Pharmacokinetic Modeling of Acetaminophen Protein Adducts in Adults and Children.J Clin Pharmacol. 2020 May;60(5):595-604. doi: 10.1002/jcph.1555. Epub 2019 Dec 4. J Clin Pharmacol. 2020. PMID: 31802503 Free PMC article.
-
Pharmacokinetics of intravenous paracetamol in elderly patients.Clin Pharmacokinet. 2011 Feb;50(2):121-9. doi: 10.2165/11537240-000000000-00000. Clin Pharmacokinet. 2011. PMID: 21241071
-
The Role of Community Pharmacists in the Detection of Clinically Relevant Drug-Related Problems in Chronic Kidney Disease Patients.Pharmacy (Basel). 2020 May 22;8(2):89. doi: 10.3390/pharmacy8020089. Pharmacy (Basel). 2020. PMID: 32456115 Free PMC article.
-
Opioid Safety and Concomitant Benzodiazepine Use in End-Stage Renal Disease Patients.Pain Res Manag. 2019 Oct 20;2019:3865924. doi: 10.1155/2019/3865924. eCollection 2019. Pain Res Manag. 2019. PMID: 31772694 Free PMC article.
-
Characterizing the Effects of Race/Ethnicity on Acetaminophen Pharmacokinetics Using Physiologically Based Pharmacokinetic Modeling.Eur J Drug Metab Pharmacokinet. 2017 Feb;42(1):143-153. doi: 10.1007/s13318-016-0329-2. Eur J Drug Metab Pharmacokinet. 2017. PMID: 26972700
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical